Skip to main content
. 2017 Feb;6(1):42–51. doi: 10.21037/tlcr.2016.11.05

Table 1. Baseline results of selected European low-dose computed tomography lung cancer screening trials.

Variables UKLS (21) DANTE (4,22) DLCST (4,23) NELSON (4,24,25) ITALUNG (4,26) LUSI (4,27)
Participants
   Received CT screening 1,994 1,276 2,052 7,557 1,406 2,029
   Age, mean [SD] 67 [4] 65 [5] 57 [5] 59 [6] 61 [4] 58 [5]
   Pack years, mean [SD] NA 47 [25] 36 [13] 42 [19] 43 [18] 36 [18]
Nodule detection limit ≥15 mm3/≥3 mm None reported None reported ≥15 mm3 ≥5 mm ≥5 mm
Participants with lung cancer 42/1,994 (2.1%) 28/1,276 (2.2%) 17/2,052 (0.8%) 70/7,557 (0.9%) 20/1,406 (1.4%) 22/2,029 (1.1%)
Participants with NCNs 1,015/1,994 (50.9%) NA 447/2,052 (21.8%) 3,816/7,557 (50.5%) 426/1,406 (30.3%) 540/2,029 (26.6%)
% with lung cancer 42/1,015 (4.1%) NA 17/447 (3.8%) 70/3,816 (1.8%) 20/426 (4.7%) 22/540 (4.1%)
% of NCNs being lung cancer NA NA 17/560 (3.0%) 74/8,623 (0.9%) 21/639 (3.3%) NA
Lung cancer
   Stage I 28/42 (66.7%) 16/28 (57.1%) 9/17 (53.0%) 48/74 (64.9%) 10/21 (47.6%) 18/22 (81.8%)
   Histology
      Adenocarcinoma 25/42 (59.5%) 17/28 (60.7%) 12/17 (70.6%) 37/74 (50.0%) 10/21 (47.6%) 15/22 (68.2%)
      Squamous-cell carcinoma 12/42 (28.6%) 8/28 (28.6%) 2/17 (11.8%) 15/74 (20.3%) 6/20 (30.0%) 3/22 (13.6%)
      Small-cell Lung cancer 3/42 (7.1%) 2/28 (7.1%) 0 1/74 (1.4%) 1/21 (4.7%) 1/22 (4.5%)
      Others 2/42 (4.8%) 1/28 (3.6%) 3/17 (17.6%) 21/74 (28.4%) 4/21 (19.0%) 3/22 (13.6%)

, bronchioloalveolar carcinomas are considered adenocarcinomas. UKLS, United Kingdom lung screening trial; DANTE, detection and screening of early lung cancer by novel imaging technology and molecular assays; DLCST, Danish lung cancer screening trial; NELSON, Dutch-Belgian lung cancer screening trial; ITALUNG, Italian lung study; LUSI, German lung cancer screening intervention study; SD, standard deviation; NCNs, non-calcified pulmonary nodules; NA, not available.